Mycenax Competitors

Stocks . Taiwan . 
Stock . Mycenax Biotech
4726 Stock  TWD 35.45  0.05  0.14%   
Mycenax Biotech competes with Taigen Biopharmaceutica, OBI Pharma, Sinphar Pharmaceutical, Adimmune Corp, and Panion BF; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Mycenax Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mycenax Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Mycenax Biotech Correlation with its peers.

Mycenax Biotech vs Panion BF Correlation

Weak diversification

The correlation between Mycenax Biotech and 1760 is 0.34 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Mycenax Biotech and 1760 in the same portfolio, assuming nothing else is changed.

Moving together with Mycenax Stock

  0.714743 Oneness BiotechPairCorr

Moving against Mycenax Stock

  0.626712 Ever Supreme BioPairCorr
  0.532538 Kee Tai PropertiesPairCorr
  0.496541 Tanvex BioPharmaPairCorr
  0.486186 Shin Ruenn DevelopmentPairCorr
  0.361416 Kwong Fong IndustriesPairCorr
Hype
Prediction
LowEstimatedHigh
33.0935.4537.81
Details
Intrinsic
Valuation
LowRealHigh
26.4828.8439.00
Details
Naive
Forecast
LowNextHigh
32.6034.9637.33
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
29.4433.3937.35
Details

Mycenax Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mycenax Biotech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mycenax and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mycenax Biotech does not affect the price movement of the other competitor.

High positive correlations

6976
+ 0.77
6875
1734
+ 0.67
6586
1760
+ 0.35
1734
6976
+ 0.33
6586
1760
+ 0.33
4142
1760
+ 0.32
6586
  

High negative correlations

4157
- 0.54
6586
1760
- 0.45
7754
1734
- 0.35
4157
4142
- 0.34
1734
6976
- 0.33
4142
4142
- 0.3
6875

Risk-Adjusted Indicators

There is a big difference between Mycenax Stock performing well and Mycenax Biotech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mycenax Biotech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Mycenax Biotech Competitive Analysis

The better you understand Mycenax Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mycenax Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mycenax Biotech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4726 6586 6875 4157 4174 1734 4142 6976 7754 1760
 0.14 
 35.45 
Mycenax
 0.18 
 28.10 
CHO
 0.75 
 46.55 
Pharmosa
 3.85 
 14.85 
Taigen
 112.31 
 55.20 
OBI
 0.48 
 31.15 
Sinphar
 4.43 
 20.05 
Adimmune
 1.05 
 14.15 
Acepodia
 0.30 
 50.00 
7754
 1.97 
 67.30 
Panion
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Not too volatile
Somewhat reliable
Very steady
Very steady
Not too volatile
Very steady
Very steady
Market Performance
(90 Days Performance)
Soft
Weakest
Weakest
Solid
Fair
Weakest
Soft
Weakest
Mild
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Fair
Unknown
Small
High
Small
Low
Unknown
Unknown
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Fairly Valued
Fairly Valued
Under Valued
Fairly Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Strong Sell
Sell
Strong Hold
Buy
Hold
Cautious Hold
Current Ratio
2.56
N/A
N/A
N/A
35.63
2.25
1.34
N/A
N/A
1.5
Net Asset
3.14 B
N/A
N/A
1.39 B
4.49 B
6.22 B
8.01 B
N/A
N/A
2.95 B
Profit Margin
-0.43
N/A
N/A
N/A
N/A
0.0725
0.21
N/A
N/A
0.11
EBITDA
82.83 M
N/A
N/A
905.1 M
(1.52 B)
109.64 M
254.89 M
N/A
N/A
340.96 M
Operating Margin
-0.43
N/A
N/A
-9.4
-311.15
0.0747
0.0783
N/A
N/A
0.17
Current Valuation
6.82 B
N/A
N/A
11.41 B
12.29 B
6.26 B
15.44 B
N/A
N/A
15.29 B
Price To Book
3.21
N/A
N/A
11.51
3.33
1.88
2.47
N/A
N/A
7.27
Retained Earnings
N/A
N/A
N/A
N/A
N/A
237 M
(253 M)
N/A
N/A
N/A
Current Asset
N/A
N/A
N/A
N/A
N/A
2.28 B
1.75 B
N/A
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
1.48
N/A
N/A
N/A
N/A
Beta
0.99
N/A
N/A
0.93
1.3
0.79
0.54
N/A
N/A
0.52
Number Of Employees
334
11
N/A
23
48
26
36
N/A
N/A
16
Shares Outstanding
155.31 M
N/A
N/A
716.84 M
228.95 M
167.72 M
421.51 M
N/A
N/A
85.74 M
Cash Flow From Operations
(146.23 M)
N/A
N/A
629.07 M
(1.06 B)
135.54 M
(480.52 M)
N/A
N/A
401.23 M
Annual Yield
N/A
N/A
N/A
N/A
N/A
0.0063
0.0135
N/A
N/A
0.0088
Total Debt
474.4 M
N/A
N/A
N/A
28 M
1.49 B
1.27 B
N/A
N/A
116.07 M
Return On Equity
-0.17
N/A
N/A
-0.21
-0.34
0.0444
0.0655
N/A
N/A
0.14
Z Score
7.8
N/A
N/A
N/A
N/A
1.8
7.8
N/A
N/A
75.0
Return On Asset
-0.0639
N/A
N/A
-0.15
-0.22
0.0207
0.0139
N/A
N/A
0.0805
Book Value Per Share
12.38
N/A
N/A
1.5
22.55
17.41
14.63
N/A
N/A
24.55
Current Liabilities
N/A
N/A
N/A
N/A
N/A
999 M
732 M
N/A
N/A
N/A
Total Asset
3.14 B
N/A
N/A
1.39 B
4.49 B
6.22 B
8.01 B
N/A
N/A
2.95 B
Debt To Equity
0.043
N/A
N/A
N/A
0.056
51.5
206.9
N/A
N/A
0.93
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
0.2
N/A
N/A
N/A
1.5
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
35.0
N/A
N/A
106.0
Shares Owned By Institutions
0.04
N/A
N/A
24.94
5.0
1.49
15.86
N/A
N/A
0.68
Market Capitalization
6.22 B
5.44 B
N/A
11.33 B
17.7 B
5.4 B
17.01 B
N/A
N/A
14.53 B
Price To Earning
25.96
N/A
N/A
N/A
N/A
536.84
-7.22
N/A
N/A
N/A
Price To Sales
7.93
N/A
N/A
369.99
2516.59
2.15
6.17
N/A
N/A
6.42
Net Income
(89.86 M)
N/A
N/A
775.62 M
(1.53 B)
(38.13 M)
43.07 M
N/A
N/A
104.4 M
Earnings Per Share
-1.22
N/A
N/A
1.08
-8.05
1.18
1.2
N/A
N/A
3.15
Shares Owned By Insiders
52.0
N/A
N/A
35.93
36.77
20.27
16.9
N/A
N/A
33.64
Revenue
774.27 M
N/A
N/A
1.29 B
18.77 M
2.43 B
1.64 B
N/A
N/A
1.9 B
Working Capital
N/A
N/A
N/A
N/A
N/A
1.28 B
1.02 B
N/A
N/A
N/A
Cash And Equivalents
616.63 M
N/A
N/A
N/A
3.57 B
937.43 M
654.9 M
N/A
N/A
350.7 M
Cash Per Share
4.02
N/A
N/A
N/A
17.92
5.59
2.76
N/A
N/A
4.57
Gross Profit
135.94 M
N/A
N/A
1.28 B
(25.59 M)
888.71 M
464.14 M
N/A
N/A
912.14 M
Day Typical Price
35.33
28.35
46.67
15.28
54.47
31.15
20.03
14.18
49.87
67.57
Accumulation Distribution
7126.64
34439.35
8215.24
1.3 M
0.0644
5260.53
627667.0
10472.99
9039.58
16698.29
Market Facilitation Index
0.0
0.0
0.0
N/A
3.6
0.0
N/A
0.0
0.0
0.0
Daily Balance Of Power
0.0588
(0.04)
(0.19)
0.4231
8.111111
0.375
0.5862
(0.50)
0.0682
0.5417
Period Momentum Indicator
0.05
(0.05)
(0.35)
0.55
29.2
0.15
0.85
(0.15)
0.15
1.3
Rate Of Daily Change
1.0
1.0
0.99
1.04
2.12
1.0
1.04
0.99
1.0
1.02
Day Median Price
35.28
28.48
46.72
15.5
54.1
31.15
20.02
14.2
49.8
67.7
Price Action Indicator
0.2
(0.40)
(0.35)
(0.37)
15.7
0.075
0.45
(0.12)
0.27
0.25
Relative Strength Index
57.18
N/A
38.93
65.06
84.28
52.58
53.82
35.75
N/A
57.63
Coefficient Of Variation
2530.23
(990.23)
(1,167)
404.33
828.2
(4,312)
1884.12
(1,019)
1373.75
43304.62
Mean Deviation
1.66
1.95
1.8
2.47
4.53
0.5001
1.41
1.1
1.97
1.04
Jensen Alpha
0.1042
(0.33)
(0.23)
0.7583
1.95
(0.02)
0.0541
(0.20)
0.1983
(0.02)
Total Risk Alpha
(0.14)
(0.60)
(0.48)
0.4852
0.3685
(0.09)
(0.1)
(0.38)
(0.08)
(0.14)
Sortino Ratio
0.007
N/A
N/A
0.327
0.655
N/A
0.018
N/A
0.0798
(0.07)
Downside Variance
4.1
N/A
N/A
4.85
6.21
N/A
3.03
N/A
4.47
1.29
Standard Deviation
2.36
3.05
2.62
3.23
14.17
0.7231
2.08
1.91
3.41
1.44
Kurtosis
4.04
5.66
3.52
1.09
59.4
5.77
7.27
21.58
16.33
2.79
Potential Upside
3.75
4.1
3.17
7.53
9.84
0.9983
2.7
1.66
3.37
2.58
Treynor Ratio
(0.28)
(1.67)
4.56
1.78
(0.47)
0.3269
0.1498
14.96
0.4154
(0.05)
Maximum Drawdown
13.13
18.95
17.4
16.13
17.1
4.85
14.59
14.68
22.67
7.56
Variance
5.58
9.3
6.89
10.44
200.92
0.5229
4.33
3.65
11.61
2.07
Market Risk Adjusted Performance
(0.27)
(1.66)
4.57
1.79
(0.46)
0.3369
0.1598
14.97
0.4254
(0.04)
Risk Adjusted Performance
0.036
(0.07)
(0.06)
0.1897
0.0983
(0.02)
0.0455
(0.07)
0.0614
0.0066
Skewness
1.01
1.7
0.7151
0.8749
7.53
1.41
1.63
3.67
3.3
1.35
Semi Deviation
1.88
N/A
N/A
1.73
1.58
N/A
1.57
N/A
1.81
1.06
Information Ratio
0.006
(0.13)
(0.12)
0.2228
0.1152
(0.13)
0.015
(0.14)
0.0495
(0.05)
Value At Risk
(3.34)
(4.33)
(3.56)
(2.79)
(3.22)
(0.98)
(2.65)
(2.37)
(3.14)
(1.85)
Expected Short fall
(2.10)
N/A
N/A
(3.20)
(6.56)
N/A
(1.70)
N/A
(2.43)
(1.37)
Downside Deviation
2.02
N/A
N/A
2.2
2.49
N/A
1.74
N/A
2.12
1.13
Semi Variance
3.54
N/A
N/A
2.99
2.5
N/A
2.47
N/A
3.29
1.12

Mycenax Biotech Competition Performance Charts

Five steps to successful analysis of Mycenax Biotech Competition

Mycenax Biotech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mycenax Biotech in relation to its competition. Mycenax Biotech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mycenax Biotech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mycenax Biotech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mycenax Biotech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mycenax Biotech position

In addition to having Mycenax Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks
Soft Drinks Theme
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 6 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Mycenax Stock Analysis

When running Mycenax Biotech's price analysis, check to measure Mycenax Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mycenax Biotech is operating at the current time. Most of Mycenax Biotech's value examination focuses on studying past and present price action to predict the probability of Mycenax Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mycenax Biotech's price. Additionally, you may evaluate how the addition of Mycenax Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY